Literature DB >> 11685457

CFFM4: a new member of the CD20/FcepsilonRIbeta family.

M C Gingras1, H Lapillonne, J F Margolin.   

Abstract

Proteins with transmembrane domains are classified in different families based on their structure, amino acid homology, and function. In this study, we report the identification, sequence, and expression profile of a new member of the CD20/FcepsilonRIbeta family, CD20/FcepsilonRIbeta family member 4 (CFFM4). The CFFM4 gene contains seven exons and six introns and is transcribed into an mRNA encoding a 240-amino acid protein with four hydrophobic regions. The CFFM4 protein shares a high degree of homology with the other members of the family, especially in the hydrophobic regions where several amino acids are conserved. However, the CFFM4 protein can be distinguished from the other members of the family based on the length of the second extracellular loop and the absence of an immunoreceptor tyrosine-based activation motif signal. Another distinct characteristic is that CFFM4 mRNA expression is not limited to the hematopoietic lineage. CFFM4 was detected by Northern dot blot in a variety of normal and cancerous tissues. CFFM4 expression was also compared in developmentally early hematopoietic human bone marrow CD34+ stem cells versus peripheral blood-derived CD14+ mature monocytes, in the undifferentiated versus differentiated myelomonocytic U937 cell line, and in acute myelogenous leukemia FAB1 versus FAB5. In each of these systems, cellular myelomonocytic differentiation correlated with an increase in CFFM4 mRNA expression. Such results indicate that CFFM4 is associated with mature cellular function in the monocytic lineage and like CD20 and FcepsilonRIbeta, it may be a component of a receptor complex involved in signal transduction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11685457     DOI: 10.1007/s002510100345

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  7 in total

Review 1.  The MS4A family: counting past 1, 2 and 3.

Authors:  Li Eon Kuek; Melanie Leffler; Graham A Mackay; Mark D Hulett
Journal:  Immunol Cell Biol       Date:  2015-04-03       Impact factor: 5.126

Review 2.  Macrophages at CNS interfaces: ontogeny and function in health and disease.

Authors:  Katrin Kierdorf; Takahiro Masuda; Marta Joana Costa Jordão; Marco Prinz
Journal:  Nat Rev Neurosci       Date:  2019-07-29       Impact factor: 34.870

3.  Analysis of the host transcriptome from demyelinating spinal cord of murine coronavirus-infected mice.

Authors:  Ruth Elliott; Fan Li; Isabelle Dragomir; Ming Ming W Chua; Brian D Gregory; Susan R Weiss
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

4.  miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.

Authors:  Anne-Laure Gagez; Isabelle Duroux-Richard; Stéphane Leprêtre; Frédérique Orsini-Piocelle; Rémi Letestu; Sophie De Guibert; Edouard Tuaillon; Véronique Leblond; Olfa Khalifa; Valérie Gouilleux-Gruart; Anne Banos; Olivier Tournilhac; Jehan Dupuis; Christian Jorgensen; Guillaume Cartron; Florence Apparailly
Journal:  Haematologica       Date:  2017-01-25       Impact factor: 9.941

5.  Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages.

Authors:  Sean P Arlauckas; Seth B Garren; Chris S Garris; Rainer H Kohler; Juhyun Oh; Mikael J Pittet; Ralph Weissleder
Journal:  Theranostics       Date:  2018-11-12       Impact factor: 11.556

6.  IKAP-Identifying K mAjor cell Population groups in single-cell RNA-sequencing analysis.

Authors:  Yun-Ching Chen; Abhilash Suresh; Chingiz Underbayev; Clare Sun; Komudi Singh; Fayaz Seifuddin; Adrian Wiestner; Mehdi Pirooznia
Journal:  Gigascience       Date:  2019-10-01       Impact factor: 6.524

7.  Distinct Expression and Prognostic Value of MS4A in Gastric Cancer.

Authors:  Lei Sun; Yanli Zhang; Chao Zhang
Journal:  Open Med (Wars)       Date:  2018-05-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.